From: Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients
A | Â | Disease specific survival | Overall survival | ||||||
 |  | Regression model without NFE2L2 mRNA expression | Regression model incl. NFE2L2 mRNA expression | Regression model without NFE2L2 mRNA expression | Regression model incl. NFE2L2 mRNA expression | ||||
Variable | Â | HR (95Â % CI) | P | HR (95Â % CI) | P | HR (95Â % CI) | P | HR (95Â % CI) | P |
Size | T1 vs. T2/3/4 | 1.5 (1.2–2.0) | 0.003 | 1.5 (1.2–2.0) | 0.002 | 1.5 (1.2–1.8) | 0.001 | 1.5 (1.2–1.9) | 0.001 |
LN | neg. vs. pos. | 1.7 (1.2–2.3) | 0.002 | 1.7 (1.2–2.4) | 0.001 | 1.5 (1.2–2.0) | 0.002 | 1.6 (1.2–2.1) | 0.001 |
Tumour grade | I vs. II vs. III | 1.4 (1.1 -1.9) | 0.008 | 1.4 (1.1 -1.8) | 0.014 | 1.3 (1.0 -1.6) | 0.026 | 1.3 (1.0 -1.6) | 0.043 |
MP | pre vs. post | 1.3 (0.9–1.7) | 0.139 | 1.2 (0.9–1.7) | 0.175 | 1.7 (1.2–2.2) | <0.001 | 1.6 (1.2–2.1) | 0.001 |
HER2 | neg. vs. pos. | 1.6 (1.2–2.2) | 0.002 | 1.7 (1.2–2.2) | 0.001 | 1.5 (1.1–2.0) | 0.004 | 1.5 (1.2–2.0) | 0.002 |
ER | neg. vs. pos. | 1.2 (0.8–1.8) | 0.432 | 1.2 (0.8–1.7) | 0.466 | 1.1 (0.8–1.6) | 0.449 | 1.1 (0.8–1.6) | 0.496 |
Histology |  | 0.9 (0.7–1.2) | 0.422 | 0.9 (0.7–1.2) | 0.462 | 1.0 (0.8–1.2) | 0.641 | 1.0 (0.8–1.2) | 0.695 |
Chemotherapy | no vs. yes | 1.7 (1.1–2.5) | 0.014 | 1.7 (1.1–2.5) | 0.015 | 1.5 (1.0–2.2) | 0.027 | 1.5 (1.0–2.2) | 0.030 |
Radiation therapy | no vs. yes | 1.0 (0.7–1.3) | 0.955 | 1.0 (0.7–1.3) | 0.850 | 0.9 (0.7–1.1) | 0.298 | 0.9 (0.7–1.1) | 0.232 |
Endocrine therapy | no vs. yes | 0.8 (0.6–1.1) | 0.211 | 0.8 (0.6–1.1) | 0.232 | 0.8 (0.6–1.1) | 0.214 | 0.8 (0.6–1.1) | 0.253 |
NFE2L2 mRNA expression | low vs. high (< or > 65th %ile) | - | - | 0.8 (0.6–1.0) | 0.041 | - | - | 0.8 (0.6–1.0) | 0.023 |
B | Â | Relapse-free survival | Overall survival | ||||||
 |  | Regression model without NFE2L2 mRNA expression | Regression model incl. NFE2L2 mRNA expression | Regression model without NFE2L2 mRNA expression | Regression model incl. NFE2L2 mRNA expression | ||||
Variable | Â | HR (95Â % CI) | P | HR (95Â % CI) | P | HR (95Â % CI) | P | HR (95Â % CI) | P |
Size | T1 vs. T2/3/4 | 1.9 (0.8–4.3) | 0.120 | 2.0 (0.9–4.5) | 0.098 | 1.6 (0.8–3.2) | 0.176 | 1.6 (0.8–3.2) | 0.154 |
LN | neg. vs. pos. | 1.4 (0.7–2.9) | 0.368 | 1.3 (0.6–2.7) | 0.539 | 2.2 (1.2–4.3) | 0.015 | 2.1 (1.1–4.1) | 0.025 |
Tumour grade | I vs. II vs. III | 1.1 (0.6–2.1) | 0.709 | 1.3 (0.7–2.5) | 0.378 | 0.8 (0.5–1.2) | 0.257 | 0.8 (0.5–1.4) | 0.455 |
MP | pre vs. post | 1.0 (0.5–2.1) | 0.892 | 1.1 (0.5–2.2) | 0.817 | 2.0 (1.0–4.0) | 0.044 | 2.0 (1.0–4.0) | 0.038 |
HER2 | neg. vs. pos. | 1.0 (0.5–2.0) | 0.995 | 1.0 (0.5–2.0) | 0.995 | 1.3 (0.8–2.3) | 0.342 | 1.4 (0.8–2.4) | 0.292 |
ER | neg. vs. pos. | 0.5 (0.1–1.7) | 0.257 | 0.4 (0.1–1.5) | 0.177 | 1.0 (0.4–2.8) | 0.990 | 0.9 (0.3–2.5) | 0.824 |
PR | neg. vs. pos. | 1.0 (0.4–2.8) | 0.992 | 1.2 (0.4–3.6) | 0.726 | 1.0 (0.4–2.5) | 0.982 | 1.1 (0.5–2.9) | 0.782 |
Histology |  | 0.7 (0.4–1.3) | 0.270 | 0.6 (0.3–1.1) | 0.107 | 1.2 (0.7–2.1) | 0.533 | 1.2 (0.6–2.1) | 0.659 |
Chemotherapy | no vs. yes | 1.4 (0.7–3.0) | 0.366 | 1.3 (0.6–2.8) | 0.495 | 0.9 (0.5–1.7) | 0.831 | 0.9 (0.5–1.6) | 0.684 |
Radiation therapy | no vs. yes | 1.6 (0.8–3.1) | 0.202 | 1.5 (0.7–2.9) | 0.277 | 0.8 (0.5–1.3) | 0.374 | 0.8 (0.4–1.3) | 0.308 |
Endocrine therapy | no vs. yes | 1.2 (0.5–3.0) | 0.731 | 1.3 (0.5–3.4) | 0.563 | 0.7 (0.3–1.5) | 0.358 | 0.7 (0.4–1.5) | 0.431 |
NFE2L2 mRNA expression | low vs. high (< or > 65th %ile) | - | - | 0.4 (0.2–0.9) | 0.031 | - | - | 0.6 (0.3–1.2) | 0.135 |
 | low vs. high (< or > median) | - | - | 0.3 (0.1–0.6) | 0.001 | - | - | 0.5 (0.3–0.8) | 0.010 |